Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Invested Capital (2021 - 2025)

Historic Invested Capital for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $535.4 million.

  • Kiniksa Pharmaceuticals International's Invested Capital rose 2251.16% to $535.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $535.4 million, marking a year-over-year increase of 2251.16%. This contributed to the annual value of $438.4 million for FY2024, which is 9.18% down from last year.
  • Kiniksa Pharmaceuticals International's Invested Capital amounted to $535.4 million in Q3 2025, which was up 2251.16% from $495.0 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Invested Capital's 5-year high stood at $535.4 million during Q3 2025, with a 5-year trough of $153.5 million in Q2 2022.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Invested Capital had a median value of $405.1 million in 2023 and averaged $362.2 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Invested Capital crashed by 3858.65% in 2022 and then surged by 16819.03% in 2023.
  • Kiniksa Pharmaceuticals International's Invested Capital (Quarter) stood at $185.0 million in 2021, then surged by 114.09% to $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then fell by 0.09% to $438.4 million in 2024, then grew by 22.11% to $535.4 million in 2025.
  • Its last three reported values are $535.4 million in Q3 2025, $495.0 million for Q2 2025, and $457.5 million during Q1 2025.